BR0016669A - Composto, e, composição farmacêutica - Google Patents

Composto, e, composição farmacêutica

Info

Publication number
BR0016669A
BR0016669A BR0016669-3A BR0016669A BR0016669A BR 0016669 A BR0016669 A BR 0016669A BR 0016669 A BR0016669 A BR 0016669A BR 0016669 A BR0016669 A BR 0016669A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compound
farnesylation
compounds
methods
Prior art date
Application number
BR0016669-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Francis Thomas Boyle
James Michael Wardleworth
Zbigniew Matusiak
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0016669A publication Critical patent/BR0016669A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0016669-3A 1999-12-22 2000-12-18 Composto, e, composição farmacêutica BR0016669A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930318.2A GB9930318D0 (en) 1999-12-22 1999-12-22 Novel compounds
PCT/GB2000/004856 WO2001046137A1 (en) 1999-12-22 2000-12-18 Farnesyl transferase inhibitors

Publications (1)

Publication Number Publication Date
BR0016669A true BR0016669A (pt) 2002-10-08

Family

ID=10866834

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016669-3A BR0016669A (pt) 1999-12-22 2000-12-18 Composto, e, composição farmacêutica

Country Status (27)

Country Link
US (1) US7101897B2 (https=)
EP (1) EP1255733B1 (https=)
JP (1) JP3742593B2 (https=)
KR (1) KR20020063251A (https=)
CN (2) CN1680313A (https=)
AR (1) AR029460A1 (https=)
AT (1) ATE316074T1 (https=)
AU (1) AU776003B2 (https=)
BR (1) BR0016669A (https=)
CA (1) CA2387579A1 (https=)
CO (1) CO5360641A1 (https=)
CZ (1) CZ20022125A3 (https=)
DE (1) DE60025650D1 (https=)
EE (1) EE200200206A (https=)
GB (1) GB9930318D0 (https=)
HU (1) HUP0204135A3 (https=)
IL (1) IL149871A0 (https=)
IS (1) IS6358A (https=)
MX (1) MXPA02005981A (https=)
MY (1) MY133606A (https=)
NO (1) NO20022924L (https=)
NZ (1) NZ518341A (https=)
PL (1) PL355887A1 (https=)
RU (1) RU2259997C2 (https=)
SK (1) SK8642002A3 (https=)
WO (1) WO2001046137A1 (https=)
ZA (1) ZA200202694B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
JP4880473B2 (ja) * 2004-10-08 2012-02-22 壽製薬株式会社 ホスホン酸誘導体及び血中の高リン酸が関与する疾患の治療剤
WO2007092285A2 (en) * 2006-02-02 2007-08-16 Link Medicine Corporation Treatment of synucleinopathies
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
JP2012508768A (ja) 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
WO2011088126A2 (en) * 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors
WO2018132791A1 (en) 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU422723A1 (ru) * 1972-03-29 1974-04-05 Б. В. Салов, Т. А. Губенкова , И. В. Быховска Способ получения 5-нитро-2-аминобензойнойкислоты
CA1283906C (en) 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
JPS60233076A (ja) 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
EP0182213B1 (en) 1984-11-08 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Carbapenem compounds and production thereof
KR880006244A (ko) 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
GB8921635D0 (en) 1989-09-25 1989-11-08 Fujisawa Pharmaceutical Co 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
CA2036163C (en) 1990-02-14 2001-06-19 Makoto Sunagawa Novel beta-lactam compounds and their production
IE910606A1 (en) 1990-02-23 1991-08-28 Sankyo Co Carbapenem derivatives having antibiotic activity, their¹preparation and their use
GB9107363D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
US6083917A (en) 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5185248A (en) 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
JPH0578360A (ja) 1991-01-31 1993-03-30 Banyu Pharmaceut Co Ltd 2−[2−(スルフアモイルアルキル)ピロリジニルチオカルバペネム誘導体
GB9107341D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
GB9107342D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
RU2093514C1 (ru) 1991-06-04 1997-10-20 Санкио Компани Лимитед Производные 1-метилкарбапенема и способ их получения
JPH04368386A (ja) 1991-06-18 1992-12-21 Sankyo Co Ltd 1−メチルカルバペネム−3−カルボン酸の製造法
US5360798A (en) 1991-07-04 1994-11-01 Shionogi Seiyaku Kabushiki Kaisha Aminooxypyrrolidinylthiocarbapenem compounds
CA2080172A1 (en) 1991-10-11 1993-04-12 Scott A. Biller Method for blocking neoplastic transformation of cells induced by ras oncogenes
JPH05239058A (ja) 1991-12-17 1993-09-17 Fujisawa Pharmaceut Co Ltd 3−ピロリジニルチオ−1−アザビシクロ[3.2.0ヘプト−2−エン−2−カルボン酸化合物
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
FI103046B1 (fi) 1992-03-11 1999-04-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrrolidinyylitiokarbapeneemijohdannaisten valmistamiseksi
GB9304156D0 (en) 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
CA2091309A1 (en) 1992-03-26 1993-09-27 Frederic H. Jung Antibiotic compounds
EP0636133A1 (en) 1992-04-13 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents
EP0581502B1 (en) 1992-07-21 1998-10-21 Zeneca Limited Antibiotic carbapenem compounds
CA2099818A1 (en) 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
EP0581501B1 (en) 1992-07-21 1998-09-09 Zeneca Limited Antibiotic carbapenem compounds
EP0590885B1 (en) 1992-09-28 2000-03-15 Zeneca Limited Antibiotic carbapenem compounds
CA2106330A1 (en) 1992-10-07 1994-04-08 Patrice J. Siret Antibiotic compounds
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
WO1995000497A1 (en) 1993-06-18 1995-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2534823B2 (ja) 1993-07-07 1996-09-18 日本電気株式会社 印刷装置
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2172125A1 (en) 1993-09-30 1995-04-06 S. Jane Desolms Inhibitors of farnesyl-protein transferase
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
US5571835A (en) 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2216564A1 (en) 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2227829A1 (en) 1995-07-31 1997-02-13 Shionogi & Co., Ltd. Pyrrolidine derivatives having phospholipase a2 inhibitory activity
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
NO307879B1 (no) * 1995-09-18 2000-06-13 Sankyo Co Nye ureaderivater med ACAT-inhiberende aktivitet og farmasøytisk preparat inneholdende disse
JPH1050029A (ja) 1996-05-28 1998-02-20 Nobuyuki Higuchi 情報記憶装置
AU4020897A (en) 1996-08-17 1998-03-06 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
WO1998032741A1 (en) 1997-01-29 1998-07-30 Zeneca Limited Inhibitors of farnesyl protein transferase
JP2002518985A (ja) 1997-05-07 2002-06-25 ユニバーシティー・オブ・ピッツバーグ タンパク質イソプレニルトランスフェラーゼの阻害剤
EP1054865A1 (en) * 1998-02-10 2000-11-29 AstraZeneca UK Limited Farnesyl transferase inhibitors

Also Published As

Publication number Publication date
EP1255733A1 (en) 2002-11-13
KR20020063251A (ko) 2002-08-01
CO5360641A1 (es) 2004-01-30
ATE316074T1 (de) 2006-02-15
DE60025650D1 (de) 2006-04-06
CA2387579A1 (en) 2001-06-28
EE200200206A (et) 2003-04-15
AR029460A1 (es) 2003-07-02
PL355887A1 (en) 2004-05-31
HUP0204135A3 (en) 2005-03-29
NZ518341A (en) 2004-01-30
NO20022924D0 (no) 2002-06-18
US7101897B2 (en) 2006-09-05
CZ20022125A3 (cs) 2002-09-11
US20030083348A1 (en) 2003-05-01
AU2201301A (en) 2001-07-03
RU2259997C2 (ru) 2005-09-10
RU2002119405A (ru) 2004-01-10
SK8642002A3 (en) 2002-12-03
AU776003B2 (en) 2004-08-19
JP2003518091A (ja) 2003-06-03
EP1255733B1 (en) 2006-01-18
WO2001046137A1 (en) 2001-06-28
CN1680313A (zh) 2005-10-12
CN1411442A (zh) 2003-04-16
ZA200202694B (en) 2003-12-31
NO20022924L (no) 2002-06-18
GB9930318D0 (en) 2000-02-09
IS6358A (is) 2002-04-23
JP3742593B2 (ja) 2006-02-08
CN1229344C (zh) 2005-11-30
MY133606A (en) 2007-11-30
HUP0204135A2 (hu) 2003-03-28
IL149871A0 (en) 2002-11-10
MXPA02005981A (es) 2005-07-01

Similar Documents

Publication Publication Date Title
ATE177420T1 (de) Cyclobutan-derivate als inhibitoren der squalen- synthetase und der protein-farnesyltransferase
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
LU91145I9 (https=)
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
TNSN08038A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
PT1246809E (pt) Compostos de 5-aril-1h-1,2,4-triazole como inibidores de ciclooxigenase-2 e composicoes farmaceuticas que os contem
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
PL346019A1 (en) Nimesulide containing topical pharmaceutical compositions
BR0016669A (pt) Composto, e, composição farmacêutica
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2001042243A3 (en) Protein kinase inhibitors
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
NZ326283A (en) Diphenyl stilbenes as prodrugs to cox-2 inhibitors
WO2004060878A3 (en) Inhibitors of phosphatases
BR0016667A (pt) Composto, e, composição farmacêutica
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.